AspiriN To Inhibit SEPSIS (ANTISEPSIS) randomised controlled trial protocol.

ABSTRACT:

Introduction

Sepsis is a leading global cause of morbidity and mortality, and is more common at the extremes of age. Moreover, the cost of in-hospital care for elderly patients with sepsis is significant. There are indications from experimental and observational studies that aspirin may reduce inflammation associated with infection. This paper describes the rationale and design of the AspiriN To Inhibit SEPSIS (ANTISEPSIS) trial, a substudy of ASPirin in Reducing Events in the Elderly (ASPREE). ANTISEPSIS primarily aims to determine whether low-dose aspirin reduces sepsis-related deaths in older people. Additionally, it will assess whether low-dose aspirin reduces sepsis-related hospitalisations and sepsis-related Intensive Care Unit (ICU) admissions.

Methods and analysis

AS

SUBMITTER: Eisen DP 

PROVIDER: S-EPMC5253551 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature